Oncology
 |
|
26 march 2020 09:02:33 |
| KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC (Future Oncology) |
|
Tweet Future Oncology, Volume 16, Issue 10, Page 507-516, April 2020. |
| 204 viewsCategory: Oncology |
 Correction: UDP-glucose 6-dehydrogenase regulates hyaluronic acid production and promotes breast cancer progression (Oncogene)ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (Future Oncology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
